$5.64
9.32% yesterday
Nasdaq, Nov 15, 10:08 pm CET
ISIN
US92915B1061
Symbol
VYGR
Sector
Industry

Voyager Therapeutics, Inc. Stock News

Neutral
Seeking Alpha
3 days ago
Voyager Therapeutics, Inc. (NASDAQ:VYGR ) Q3 2024 Results Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Trista Morrison - Chief Corporate Affairs Officer and Chief of Staff to the CEO Alfred Sandrock - President and Chief Executive Officer Toby Ferguson - Chief Medical Officer Todd Carter - Chief Scientific Officer Nathan Jorgensen - Chief Financial Officer Conferen...
Neutral
GlobeNewsWire
3 days ago
- Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer's; on track to generate top-line data H1 2025 -
Neutral
GlobeNewsWire
10 days ago
LEXINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the Company will participate in multiple upcoming investor conferences:
Neutral
GlobeNewsWire
11 days ago
LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report third quarter 2024 financial and operating results after market close on Tuesday, November 12, 2024. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET.
Neutral
GlobeNewsWire
3 months ago
LEXINGTON, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, has entered into an employment agreement with a newly hired employee that, among other things, provides for the grant to such employee of a non-qualified stock option and restricted stock units as an inducement material to such emp...
Neutral
GlobeNewsWire
3 months ago
LEXINGTON, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in multiple upcoming investor conferences:
Positive
Seeking Alpha
3 months ago
Voyager Therapeutics, Inc. initial safety and PK data from the phase 1a study using VY7523 for the treatment of patients with Alzheimer's Disease expected 1st half of 2025. Targeting the C-terminal for AD patients instead of N-terminal domain could end up resulting in a significantly greater reduction of tau protein. The global Alzheimer's Disease Therapeutics market is expected to reach $30.8 ...
Neutral
InvestorPlace
3 months ago
With the market struggling amid rising recession fears, now may be the ideal time to consider biotech stocks. First, the sector itself is a financially lucrative one.

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today